HeartBeam Inc.'s VALID-ECG Study Confirms High Diagnostic Accuracy of Synthesized 12-Lead ECG

HeartBeam Inc. (NASDAQ: BEAT) has announced a significant milestone in cardiac care technology with its VALID-ECG study results. The study confirmed that the company's synthesized 12-lead ECG device achieved a 93.4% diagnostic agreement with standard ECGs for arrhythmia assessment. This breakthrough was presented by Dr. Thomas Deering of Piedmont Heart Institute at the Heart Rhythm Society's annual meeting in San Diego, highlighting the potential of HeartBeam's compact, patient-friendly ECG technology.

The VALID-ECG study involved 198 patients across five U.S. clinical sites, comparing ECG intervals and amplitudes between HeartBeam's synthesized output and standard ECGs collected simultaneously. The findings support HeartBeam's FDA submission for its ECG synthesis software, filed in January 2025. CEO Robert Eno underscored the importance of this technology in enabling accurate, on-demand arrhythmia monitoring outside traditional medical facilities, a development that could revolutionize cardiac care.

With FDA clearance on the horizon, HeartBeam has initiated an Early Access Program to fine-tune clinical workflows in preparation for its U.S. market entry. This advancement represents a pivotal moment in making cardiac health management more accessible and efficient, potentially reducing the need for hospital visits and enabling timely interventions for patients with arrhythmias.